Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib/II, Open-label, Multi-center Study of INC280 in Combination With PDR001 or PDR001 Single Agent in Advanced Hepatocellular Carcinoma.

NCT02795429 is registered in ClinicalTrials.gov with Novartis Pharmaceuticals as lead sponsor.

NCT NCT02795429
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02795429 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib/II, Open-label, Multi-center Study of INC280 in Combination With PDR001 or PDR001 Single Agent in Advanced Hepatocellular Carcinoma.
Lead sponsor
Novartis Pharmaceuticals
Phase
Phase 1/2
Overall status
Completed
Start date
June 15, 2016
Completion date
June 24, 2021
Enrollment
89 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

advanced hepatocellular carcinoma